Metabolic syndrome in schizophrenia: how much is attributable to drug treatment?


  • Harish Kumar Department of Psychiatry, MAMC, Agroha, Hisar, Haryana
  • Rajiv Gupta Department of Psychiatry, Pt BDS PGIMS, Rohtak, Haryana
  • Sonal Dogra Medical Officer, Haryana Civil Medical Services, Rohtak, Haryana
  • Rajneesh Kumar Joshi Medical Officer, National AIDS Research Institute, Pune, Maharashtra


Schizophrenia, First episode, Drug naïve, Olanzapine, Quetiapine


Background: This study was planned to investigate new onset metabolic syndrome (MS) and its various components associated with two widely used second generation antipsychotics i.e. olanzapine and quetiapine in the management of schizophrenia using International Diabetic Federation (IDF) criteria.

Methods: A total of 60 drug naïve patients with ICD-10 diagnosis of first episode schizophrenia, divided in two groups of 30 patients each, were randomly allocated to receive two different treatments i.e. olanzapine and quetiapine. Metabolic parameters were measured at day 0, then at 6 and 12 weeks. For categorical variables, ‘Chi-square test’ was used for comparison between the two groups.For continuous variables student’s t-test was used.

Results: At 6 weeks none of the patient, treated with olanzapine, developed Metabolic Syndrome (MS), but among quetiapine group 3.33% (1 out of 30) developed MS. At the end of 12 weeks, 20% patients (i.e. 6 out of 30) had MS in olanzapine treatment group and 10% (3 out of 30) in quetiapine treatment group.

Conclusion: Both olanzapine and quetiapine were found to cause comparable metabolic derangement and metabolic syndrome.



Brown S. Excess mortality of schizophrenia, a meta- analysis. Br J Psychiatry. 1997;171:502-8.

DeHert M, Winkel R, Vaneyck D, Hanssens L, Wampers M Scheen et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006;83:87-93.

Kato MM, Currier MB, Gomez CM, Hall L, Gonzalez-Blanco M. Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. Primary Care Companion J Clin Psychiatry. 2004;6:74-7.

Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry. 2004;184:58-62.

DeHert M, Eyck VD, Wampers M, Hanssens L, Scheen A, Peuskens J. Prevalence and incidence rates of metabolic abnormalities and diabetes in a prospective study of patients treated with second-generation antipsychotics. Schizophr Bull. 2007;33:560.

Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramerez-Bonilla ML, Gonzalez-Blanch C et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry. 2007;68(11):1733-40.

DeHert M, Schreurs V, Sweers K, Eyck VD, Hanssens L, Sinko S et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review. Schizophr Res. 2008;101:295-303.

Saddichha S, Ameen S, Akhtar S. Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six-week prospective study in Indian female patients. Schizophr Res. 2007;95:247.

Saddichha S, Manjunatha N, Ameen S, Akhtar S. Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled short-term prospective study. Schizophr Res. 2008;101:266-72.

Perloff D, Grim C, Flack Jl. Human blood pressure determination by sphygmomanometry. Circulation. 1993;88(5):2460-70.

Ford ES. Prevalence of metabolic syndrome defined by the international diabetes federation among adults in the US. Diabet Care. 2005;28:2745.

Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabet Care. 2003;26:575-81.

Wetterling T. Bodyweight gain with atypical antipsychotics: acomparative review. Drug Safety. 2001;24:59-73.

Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry. 2002;14:59-64.




How to Cite

Kumar, H., Gupta, R., Dogra, S., & Joshi, R. K. (2017). Metabolic syndrome in schizophrenia: how much is attributable to drug treatment?. International Journal of Research in Medical Sciences, 2(2), 569–574. Retrieved from



Original Research Articles